Takeda's GI drug continues to be growth-driver for company — 8 insights

Takeda's ulcerative colitis drug Entyvio was one of the key products behind a 10.5 percent increase in underlying revenue for the third quarter of fiscal year 2018.

Six details to know:

1. Takeda's gastroenterology, oncology, neuroscience and emerging market divisions drove the 4.8 percent underlying revenue growth.

2. The key products contributing to revenue growth were Entyvio (35.1 percent) and Ninlaro (36.6 percent).

3. Takeda's underlying core earnings grew 32.3 percent. Reported operating profit declined 11.7 percent.

4. The company's operating free cash flow decreased 20.2 percent because the drugmaker sold additional products related to Teva.

5. Takeda reported 1.4 trillion yen in revenue ($12.52 billion).

6. Takeda will revise its full year guidance in April, once Shire is incorporated into the company.

7. Takeda CFO Costa Saroukos said, "Takeda's strategic focus and superior execution continue to drive robust performance through the first three quarters of fiscal year 2018. In addition to strong commercial execution, we have continued to deliver on our commitment to margin expansion, with the Underlying Core Earnings margin increasing by 530 basis points driven by our Global Opex Initiative."

8. Takeda's fourth quarter earnings will be its first with Shire fully acquired by the company.

More articles on surgery centers:
Quality improvement, surveillance approaches needed in ASCs, study finds
Removing gloves can contaminate healthcare personnel's skin: 3 study insights
Surgical smoke is comparable to 27+ cigarettes, AORN says — 3 things to know


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers